Echosens names Romain Baujard group CEO

Echosens has appointed Romain Baujard as group chief executive officer, effective May 1.

Baujard succeeds Dominique Legros, who will retire after leading the company since 2019. Echosens said Legros oversaw a period of global expansion and increased clinical and commercial adoption of its technology.

Baujard joined Echosens in 2015 and most recently served as vice president of pharma. His previous responsibilities included global marketing, international commercial operations, and pharmaceutical partnerships, according to the company.

Echosens develops noninvasive medical devices and services focused on liver health. Its best-known technology is FibroScan, which uses vibration-controlled transient elastography to assess liver stiffness and related parameters without biopsy.

The company said Baujard’s appointment comes as liver health becomes a more important component of cardiometabolic care. Echosens is positioning its next phase around broader clinical adoption of noninvasive liver assessment beyond traditional hepatology and gastroenterology settings.

Under Legros, Echosens expanded FibroScan use beyond hepatology and gastroenterology into diabetology, endocrinology, and primary care. That shift reflects growing attention to metabolic dysfunction-associated steatotic liver disease and the overlap between liver disease, diabetes, obesity, and cardiovascular risk.

Echosens is backed by Inner Mongolia FuRui Medical Science and Astorg. The company said those investors will continue supporting its global platform and clinical adoption strategy.

“Romain’s appointment marks a new chapter for Echosens,” Legros said in the company announcement.

Baujard said Echosens has an opportunity to make liver health “a true vital sign” in cardiometabolic care.

For imaging and liver-assessment markets, the leadership change is notable because Echosens sits at the intersection of ultrasound-based technology, chronic disease screening, and noninvasive diagnostics. The company’s growth strategy will depend on how widely liver assessment is adopted in specialties that manage metabolic risk, not only in specialist liver clinics.

The appointment is a leadership transition rather than a product launch or regulatory update. Its practical impact will depend on whether Echosens can expand FibroScan use in broader care pathways, strengthen pharmaceutical partnerships, and support earlier identification of patients at risk of progressive liver disease.